Kineta, Inc.

10:00 AM - 10:15 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. We have leveraged our expertise in immunology to advance a focused pipeline of investigational drugs in immuno-oncology, neuroscience and biodefense.

RIG-I Immuno-oncology: Disruptive small molecule technology to turn cold tumors hot.
Neuroscience: a novel non-opioid to treat chronic pain.
Biodefense: a first-in-class antiviral treatment to treat Lassa fever and other arenaviruses

We actively collaborate with a broad array of industry, government and academic partners to advance our innovative research.

- $520M RIG-I immuno-oncology strategic partnership with Pfizer
- $359M chronic pain strategic partnership with Genentech
- $9M Translation Fund Award from the Wellcome Trust for LHF-535

Kineta, Inc. is raising $40 million in a crossover funding round in the second half of 2019 and planning for a public market offering in 2020.
Company Type:
Company Website:
Company HQ State:
Washington
Company HQ Country:
United States
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
RIG-I Immuno-oncology
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
Kineta, Inc.